• Agendia launches its diagnostic test TargetPrint for breast cancer patients.
• Due to expansion of the company, Agendia moves its headquarter to the Amsterdam Science Park in spring 2008.
• Foundation of Agendia Inc. in the US.

2007

• Major studies and trials initiated for further application and validation of new diagnostic oncology tests in breast cancer and other types of cancer.
• Agendia announces discovery of new gene
expression profile for colon cancer.

• CLIA registration of Agendia laboratory.
• MammaPrint acquires 510K clearance from the FDA under the newly defined IVDMIA regulations, and a second clearance for the MammaPrint sampling and shipping procedure at room temerature.

2006

• CupPrint acquires CE marking.

2005

• ISO 17025 accreditation of Agendia laboratory.
• MammaPrint acquires CE marking.
• Development of global network of subsidiary companies and agents/distributors begins.
• Agendia launches second commercial test, CupPrint.

2004

• Agendia launches its first clinically validated product, MammaPrint, based on the gene signature resulting from Bernards and van´t Veer’s original work.
  

2003

• Agendia launches its DiscoverPrint service.
• Foundation of Agendia by Dr. Bernhard Sixt, Prof. Dr. Rene Bernhards and Dr. Laura van`t Veer.

2002

• Van´t Veer and Bernards publish an mRNA based method for genomic profiling that predicts the clinical outcome of breast cancer ( van´t Veer et al, Nature, vol 415, 31 January 2002, 530-535, van de Vijver et al., New England Journal of Medicine, vol 347, no 25, 19 December 2002 ).